SG10201912735TA - Pharmaceutical composition of s-ketamine hydrochloride - Google Patents

Pharmaceutical composition of s-ketamine hydrochloride

Info

Publication number: SG10201912735TA
Authority: SG; Singapore
Prior art keywords: pharmaceutical composition; ketamine hydrochloride; ketamine; hydrochloride; pharmaceutical
Prior art date: 2013-03-15

Application number

SG10201912735TA

Inventor

Esther D G Basstanie

Johanna Bentz

Roger C A Embrechts

Nico Rudolph Niemeijer

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2020-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201912735T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2020-02-27 Publication of SG10201912735TA publication Critical patent/SG10201912735TA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

SG10201912735TA 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride SG10201912735TA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361791505P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
SG10201912735TA true SG10201912735TA (en)	2020-02-27

Family

ID=50549465

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201912735TA SG10201912735TA (en)	2013-03-15	2014-03-14	Pharmaceutical composition of s-ketamine hydrochloride
SG10201802106TA SG10201802106TA (en)	2013-03-15	2014-03-14	Pharmaceutical composition of s-ketamine hydrochloride
SG11201507358VA SG11201507358VA (en)	2013-03-15	2014-03-14	Pharmaceutical composition of s-ketamine hydrochloride

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG10201802106TA SG10201802106TA (en)	2013-03-15	2014-03-14	Pharmaceutical composition of s-ketamine hydrochloride
SG11201507358VA SG11201507358VA (en)	2013-03-15	2014-03-14	Pharmaceutical composition of s-ketamine hydrochloride

Country Status (26)

Country	Link
US (2)	US20140275277A1 (en)
EP (3)	EP3498268A1 (en)
KR (3)	KR20150129023A (en)
CN (3)	CN116251084A (en)
AU (6)	AU2014228324B2 (en)
CL (1)	CL2015002733A1 (en)
CR (1)	CR20150480A (en)
CY (1)	CY1121928T1 (en)
DK (1)	DK2968221T3 (en)
ES (1)	ES2745024T3 (en)
HR (1)	HRP20191477T1 (en)
HU (1)	HUE045982T2 (en)
LT (1)	LT2968221T (en)
ME (1)	ME03465B (en)
MX (2)	MX386479B (en)
MY (2)	MY191332A (en)
NZ (1)	NZ712270A (en)
PE (2)	PE20191796A1 (en)
PH (2)	PH12021552333A1 (en)
PL (1)	PL2968221T3 (en)
PT (1)	PT2968221T (en)
RS (1)	RS59130B1 (en)
SG (3)	SG10201912735TA (en)
SI (1)	SI2968221T1 (en)
SM (1)	SMT201900472T1 (en)
WO (1)	WO2014143646A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2897453T3 (en)	2013-09-13	2022-03-01	Univ Chiba Nat Univ Corp	Application of R-ketamine and salt thereof as pharmaceuticals
EP3094312B1 (en)	2014-01-14	2019-03-13	Children's Hospital Medical Center	Compositions comprising ketamine for treating an autism spectrum disorder
US9844551B2 (en)	2015-01-14	2017-12-19	Children's Hospital Medical Center	Compositions and methods for treatment of fragile X syndrome
US20160332962A1 (en)	2015-05-13	2016-11-17	Janssen Pharmaceutica Nv	(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN106562952B (en) *	2015-10-09	2020-06-09	江阴安博生物医药有限公司	Use of ketamine in the treatment of major depressive disorder
EP3609481A4 (en) *	2017-04-13	2021-05-26	Ovid Therapeutics Inc.	Methods of treating developmental encephalopathies
EP3641742A2 (en) *	2017-06-23	2020-04-29	Develco Pharma Schweiz AG	Hydroxynorketamine for the use in the treatment of depression
PT3505157T (en)	2017-12-29	2022-02-18	Celon Pharma Sa	Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
WO2019160057A1 (en)	2018-02-15	2019-08-22	国立大学法人千葉大学	Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP3813808A4 (en)	2018-05-04	2022-01-26	Perception Neuroscience, Inc.	DRUG TREATMENT METHODS
EP3628313B1 (en)	2018-09-28	2025-02-12	Novohale Therapeutics, LLC	Ketamine composition for use in a method of treatment of depression by pulmonary administration
US20220062200A1 (en) *	2019-05-07	2022-03-03	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
WO2020239243A1 (en)	2019-05-31	2020-12-03	Celon Pharma S.A.	Electronically supervised administration of a pharmaceutical composition
BR112021024141A2 (en)	2019-05-31	2022-01-11	Celon Pharma Sa	Inhaler for electronically supervised parenteral administration of a pharmaceutical composition
US20220339123A1 (en) *	2019-09-13	2022-10-27	Janssen Pharmaceuticals, Inc.	Intranasal administration of esketamine
US11160799B2 (en) *	2019-10-22	2021-11-02	Cessatech A/S	Pediatric combination
TW202135787A (en) *	2019-12-12	2021-10-01	比利時商健生藥品公司	Esketamine formulations and methods for preparation and storage
CA3152593A1 (en) *	2019-12-20	2021-06-24	Tong-Ho Lin	Long-acting injectable formulations of ketamine pamoate salts
CN114903840A (en) *	2021-02-08	2022-08-16	四川普锐特药业有限公司	Low-dose R-ketamine intranasal medicament for treating depression
CN113813250B (en) *	2021-07-21	2023-05-05	广州新济药业科技有限公司	Pharmaceutical composition containing ketamine and preparation method and application thereof
CN116942648A (en)	2022-04-26	2023-10-27	宜昌人福药业有限责任公司	Liquid preparation of esketamine and application thereof
WO2023207728A1 (en)	2022-04-26	2023-11-02	宜昌人福药业有限责任公司	Esketamine liquid preparation and use thereof
AU2023390101A1 (en) *	2022-12-07	2025-06-19	Freedom Biosciences, Inc.	Treatment or prevention of depressive disorders through combination therapy
WO2025037252A1 (en) *	2023-08-14	2025-02-20	Javitt Daniel C	Compositions and methods for treatment of chronic pain and depression
US12005035B1 (en) *	2023-08-14	2024-06-11	Daniel C. Javitt	Compositions and methods for treatment of chronic pain and depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4312016A1 (en)	1993-04-13	1994-10-20	Goedecke Ag	Stable ketamine solutions
WO2002024116A1 (en) *	2000-09-20	2002-03-28	Shahinian, Lee, Jr.	Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en)	2000-10-23	2005-04-19	Shanbrom Technologies, Llc	Enhancers for microbiological disinfection
CN101466364A (en) *	2006-03-22	2009-06-24	纽约大学西奈山医学院	Intranasal administration of ketamine to treat depression
DE102007009888A1 (en) *	2007-02-28	2008-09-04	Hermann, Holger Lars, Dr.	Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder
MX2015002378A (en) *	2012-08-23	2015-09-25	Stuart L Weg	ANSIOLITIC COMPOSITION, FORMULATION AND METHOD OF USE.

2014
- 2014-03-14 EP EP19151099.9A patent/EP3498268A1/en not_active Withdrawn
- 2014-03-14 ME MEP-2019-229A patent/ME03465B/en unknown
- 2014-03-14 EP EP23194654.2A patent/EP4309735A3/en active Pending
- 2014-03-14 PT PT14719471T patent/PT2968221T/en unknown
- 2014-03-14 ES ES14719471T patent/ES2745024T3/en active Active
- 2014-03-14 MX MX2019000742A patent/MX386479B/en unknown
- 2014-03-14 MY MYPI2015703106A patent/MY191332A/en unknown
- 2014-03-14 SI SI201431255T patent/SI2968221T1/en unknown
- 2014-03-14 CN CN202310142376.5A patent/CN116251084A/en active Pending
- 2014-03-14 PH PH1/2021/552333A patent/PH12021552333A1/en unknown
- 2014-03-14 SG SG10201912735TA patent/SG10201912735TA/en unknown
- 2014-03-14 SG SG10201802106TA patent/SG10201802106TA/en unknown
- 2014-03-14 PL PL14719471T patent/PL2968221T3/en unknown
- 2014-03-14 LT LTEP14719471.6T patent/LT2968221T/en unknown
- 2014-03-14 DK DK14719471.6T patent/DK2968221T3/en active
- 2014-03-14 PE PE2019002294A patent/PE20191796A1/en unknown
- 2014-03-14 NZ NZ712270A patent/NZ712270A/en unknown
- 2014-03-14 PE PE2015001997A patent/PE20160052A1/en active IP Right Grant
- 2014-03-14 WO PCT/US2014/027074 patent/WO2014143646A1/en not_active Ceased
- 2014-03-14 EP EP14719471.6A patent/EP2968221B1/en not_active Revoked
- 2014-03-14 US US14/212,988 patent/US20140275277A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029474A patent/KR20150129023A/en not_active Ceased
- 2014-03-14 KR KR1020217006306A patent/KR20210028278A/en not_active Ceased
- 2014-03-14 HR HRP20191477 patent/HRP20191477T1/en unknown
- 2014-03-14 SM SM20190472T patent/SMT201900472T1/en unknown
- 2014-03-14 AU AU2014228324A patent/AU2014228324B2/en active Active
- 2014-03-14 CN CN201911264371.XA patent/CN111297803A/en active Pending
- 2014-03-14 CN CN201480015763.1A patent/CN105073103A/en active Pending
- 2014-03-14 MX MX2015012342A patent/MX373678B/en active IP Right Grant
- 2014-03-14 KR KR1020237037938A patent/KR20230156807A/en not_active Ceased
- 2014-03-14 US US14/212,565 patent/US20140275276A1/en not_active Abandoned
- 2014-03-14 HU HUE14719471A patent/HUE045982T2/en unknown
- 2014-03-14 RS RS20191043A patent/RS59130B1/en unknown
- 2014-03-14 SG SG11201507358VA patent/SG11201507358VA/en unknown
- 2014-03-14 MY MYPI2019005662A patent/MY203693A/en unknown
2015
- 2015-09-04 PH PH12015501957A patent/PH12015501957A1/en unknown
- 2015-09-11 CR CR20150480A patent/CR20150480A/en unknown
- 2015-09-15 CL CL2015002733A patent/CL2015002733A1/en unknown
2019
- 2019-02-01 AU AU2019200705A patent/AU2019200705B2/en active Active
- 2019-02-01 AU AU2019200696A patent/AU2019200696B2/en active Active
- 2019-02-01 AU AU2019200702A patent/AU2019200702B2/en active Active
- 2019-08-23 CY CY20191100904T patent/CY1121928T1/en unknown
2021
- 2021-01-07 AU AU2021200072A patent/AU2021200072A1/en not_active Abandoned
2023
- 2023-02-20 AU AU2023200976A patent/AU2023200976B2/en active Active

Also Published As

Publication number	Publication date
AU2019200702B2 (en)	2020-10-08
EP4309735A2 (en)	2024-01-24
KR20230156807A (en)	2023-11-14
CR20150480A (en)	2015-10-26
RS59130B1 (en)	2019-09-30
NZ712270A (en)	2020-02-28
AU2023200976B2 (en)	2025-03-27
MX2015012342A (en)	2016-06-06
AU2023200976A1 (en)	2023-03-23
KR20150129023A (en)	2015-11-18
PH12021552333A1 (en)	2022-08-01
HRP20191477T1 (en)	2019-12-13
PH12015501957A1 (en)	2016-01-11
EP2968221B1 (en)	2019-06-19
BR112015022970A2 (en)	2017-07-18
HUE045982T2 (en)	2020-01-28
AU2019200696B2 (en)	2020-10-08
AU2019200696A1 (en)	2019-02-21
US20140275277A1 (en)	2014-09-18
SG10201802106TA (en)	2018-04-27
AU2014228324A1 (en)	2015-09-17
MY191332A (en)	2022-06-16
AU2014228324B2 (en)	2019-01-31
AU2019200705B2 (en)	2020-10-08
AU2021200072A1 (en)	2021-03-18
BR112015022970A8 (en)	2019-11-26
PL2968221T3 (en)	2020-01-31
LT2968221T (en)	2019-07-25
ES2745024T3 (en)	2020-02-27
PT2968221T (en)	2019-09-13
AU2019200702A1 (en)	2019-02-21
KR20210028278A (en)	2021-03-11
CL2015002733A1 (en)	2016-03-04
SG11201507358VA (en)	2015-10-29
ME03465B (en)	2020-01-20
PE20160052A1 (en)	2016-01-28
AU2019200705A1 (en)	2019-02-21
CN105073103A (en)	2015-11-18
WO2014143646A1 (en)	2014-09-18
CN111297803A (en)	2020-06-19
SMT201900472T1 (en)	2019-09-09
CY1121928T1 (en)	2020-10-14
US20140275276A1 (en)	2014-09-18
EP2968221A1 (en)	2016-01-20
MY203693A (en)	2024-07-14
PE20191796A1 (en)	2019-12-24
SI2968221T1 (en)	2019-08-30
DK2968221T3 (en)	2019-08-05
EP4309735A3 (en)	2024-04-17
EP3498268A1 (en)	2019-06-19
MX373678B (en)	2020-06-26
CN116251084A (en)	2023-06-13
MX386479B (en)	2025-03-18

Publication	Publication Date	Title
IL288961A (en)	2022-02-01	Pharmaceutical compositions
SG10201912735TA (en)	2020-02-27	Pharmaceutical composition of s-ketamine hydrochloride
SG11201507347QA (en)	2015-10-29	Pharmaceutical composition of s-ketamine hydrochloride
SMT201900684T1 (en)	2020-03-13	Combined pharmaceutical composition
PL2943181T3 (en)	2019-09-30	Pharmaceutical compositions
IL246377A0 (en)	2016-08-31	Oral pharmaceutical composition
IL243608A0 (en)	2016-02-29	Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
ZA201408333B (en)	2015-12-23	Pharmaceutical compositions
PL3043778T3 (en)	2018-04-30	Pharmaceutical compositions containing refametinib
ZA201602447B (en)	2024-05-30	Improved pharmaceutical compositions of pimobendan
SG11201509308TA (en)	2015-12-30	Low dose pharmaceutical composition
PL2991618T3 (en)	2019-08-30	Stable high strength pharmaceutical composition of levoleucovorin
IL240875B (en)	2020-08-31	Heterocyclic compounds and pharmaceutical compositions containing them
SG11201601477VA (en)	2016-04-28	Pharmaceutical composition
ZA201601645B (en)	2017-04-26	Bendamustine pharmaceutical compositions
HUP1300496A2 (en)	2015-03-02	Stable pharmaceutical composition
IL244365A0 (en)	2016-04-21	Pharmaceutical composition
AP2015008890A0 (en)	2015-11-30	Pharmaceutical compositions
GB201304699D0 (en)	2013-05-01	Pharmaceutical compositions
GB201304625D0 (en)	2013-05-01	New pharmaceutical composition
GB201321497D0 (en)	2014-01-22	Pharmaceutical compositions
GB201312851D0 (en)	2013-09-04	Pharmaceutical compositions
IL244316A0 (en)	2016-04-21	Novel drug formulation